This study involved a comprehensive clinical, genomic, and transcriptomic evaluation of FLT3 to elucidate its variations and their pathological impacts in pediatric ALL and AML, thereby informing the use of FLT3 inhibitors. Here, FLT3 is linked to acute lymphoblastic leukemia.